Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2011-06-24 Director's Dealing
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2011-06-24 English
8-K Filing
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 15, 2011, reporting the submission of matters to a vote of security holders at the company's Annual Meeting. It details the voting results for director election, auditor ratification, stock incentive plan increase, and advisory votes on executive compensation. The content focuses on official results from shareholder votes at a general meeting, which matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3843 characters, which is consistent with a detailed vote result announcement rather than a brief notice or a full report like an Annual Report or Proxy Statement. Therefore, the correct classification is DVA with high confidence.
2011-06-21 English
4 Filing
Director's Dealing
2011-06-21 English
10-Q Filing
Interim / Quarterly Report Q1 2011
2011-05-10 English
DEF 14A Filing
Proxy Solicitation & Information Statement
2011-04-29 English
8-K Filing
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically details the appointment of a new President and CEO, the resignation of the former CEO and board member, and changes in the board chairman position. It also discusses the terms of the new CEO's employment agreement. This corresponds to announcements about changes in the company's board of directors or senior management. The document does not contain financial statements or detailed financial data, so it is not an annual or interim report. It is not a proxy statement or voting results announcement. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 4129 characters, which is consistent with a typical 8-K filing for management changes. Confidence is high due to clear and explicit content about management changes.
2011-04-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.